Sign in

Trial result ·

Randomized Double-blind Placebo-controlled study to evaluate the efficacy of fermented deglycyrrhizinated licorice for treatment of diabetic polyneuropathy.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This trial tested fermented deglycyrrhizinated licorice (FDGL) capsules in early diabetic polyneuropathy (DPN). The capsules contain the enzyme α-amylase. 83 diabetic patients aged 15-65 years took part. They had diabetes for 5 years or less. They showed nerve changes on tests but no clinical DPN. They got FDGL or placebo for 6 months. 20 healthy volunteers formed a control group.

What they found

Compared with placebo, FDGL raised nerve conduction velocity (MCV and SCV) and serum amylase. It also lowered the vibration perception threshold (VPT). This held at 3 and 6 months (p < 0.001 for all outcomes). Against the control group, FDGL restored 32 and 99 of the MCV and SCV deficits. HbA1C stayed near baseline. It did not differ between the groups.

What it means for patients

The authors conclude that FDGL improved nerve conduction in diabetic patients. They say it also restored serum amylase levels. They say more studies are needed on other complications.

Why it is not certain yet

The authors say effects on other complications are not yet known. HbA1C did not change. Follow-up was 6 months. Patients had no clinical DPN at the start.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Randomized Double-blind Placebo-controlled study to evaluate the efficacy of fermented deglycyrrhizinated licorice for treatment of diabetic polyneuropathy.

PubMed · PMID 41627541

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Type 1 diabetes publications